(19)
(11) EP 3 634 951 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
21.08.2024 Bulletin 2024/34

(45) Mention of the grant of the patent:
10.07.2024 Bulletin 2024/28

(21) Application number: 18739634.6

(22) Date of filing: 08.06.2018
(51) International Patent Classification (IPC): 
C07D 213/76(2006.01)
C07D 231/38(2006.01)
C07C 381/10(2006.01)
C07D 305/08(2006.01)
C07D 307/64(2006.01)
A61P 29/00(2006.01)
 C07D 319/18(2006.01)
C07D 333/34(2006.01)
C07D 295/096(2006.01)
C07D 213/70(2006.01)
A61K 31/4406(2006.01)
C07D 215/36(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 213/76; C07D 215/36; C07D 319/18; C07D 231/38; C07D 333/34; C07C 381/10; C07D 295/096; C07D 305/08; C07D 213/70; C07D 307/64; C07C 2603/10; A61P 29/00
(86) International application number:
PCT/IB2018/054134
(87) International publication number:
WO 2018/225018 (13.12.2018 Gazette 2018/50)

(54)

NOVEL SUBSTITUTED SULFOXIMINE COMPOUNDS

NEUARTIGE SUBSTITUIERTE SULFOXIMINVERBINDUNGEN

NOUVEAUX COMPOSÉS DE SULFOXIMINE SUBSTITUÉS

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 09.06.2017 IN 201721020305

(43) Date of publication of application:
15.04.2020 Bulletin 2020/16

(73) Proprietor: Zydus Lifesciences Limited
Gujarat 382481 (IN)

(72) Inventors:
  • SHARMA, Rajiv
    Ahmedabad, Gandhinagar, Gujarat 382481 (IN)
  • IYER, Pravin
    Ahmedabad, Gandhinagar, Gujarat 382481 (IN)
  • AGARWAL, Sameer
    Ahmedabad, Gandhinagar, Gujarat 382481 (IN)

(74) Representative: Gill Jennings & Every LLP 
The Broadgate Tower 20 Primrose Street
London EC2A 2ES
London EC2A 2ES (GB)


(56) References cited: : 
WO-A1-2016/131098
WO-A1-2019/068772
US-A- 4 666 506
US-A1- 2002 077 486
 WO-A1-2019/023147
WO-A1-98/32733
US-A- 5 258 406
   
  • TOTH J E ET AL: "SULFONIMIDAMIDE ANALOGS OF ONCOLYTIC SULFONYLUREAS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 40, no. 6, 1 January 1997 (1997-01-01), pages 1018 - 1025, XP000926714, ISSN: 0022-2623, DOI: 10.1021/JM960673L
  • DATABASE PubChem Compound [online] 26 October 2006 (2006-10-26), XP002783838, retrieved from NCBI Database accession no. 10787134
  • DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 13 June 2008 (2008-06-13), XP002783839, retrieved from STN Database accession no. 1027831-60-2
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).